GLPG | tickerfilter.com

Fundamental analysis

27%

Profitability 10%

Dept financing 13%

Liquidity 75%

Performance 35%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

1.43%

1 Month

6.97%

3 Months

15.97%

6 Months

-5.85%

1 Year

-6.21%

2 Year

-32.67%

Key data

Stock price

$26.87

P/E Ratio

0.00

DAY RANGE

$26.81 - $27.50

EPS

$2.52

52 WEEK RANGE

$22.36 - $31.22

52 WEEK CHANGE

-$5.55

MARKET CAP

1.919 B

YIELD

N/A

SHARES OUTSTANDING

65.897 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-31-2025

BETA

0.75

PUBLIC FLOAT

AVERAGE 10 VOLUME

$446,727

AVERAGE 30 VOLUME

$445,711

Company detail

CEO: Paulus Stoffels
Region: US
Website: glpg.com
Employees: 1,310
IPO year: 2008

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Galapagos NV engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG.

GLPG - GALAPAGOS NV